Inc., (Nasdaq: IMGN), a leader in the expanding field of
antibody-drug conjugates (ADCs) for the treatment of cancer, today
announced that Company will host a conference call at 8:00 a.m. ET on
Friday, July 27, 2018 to discuss its second quarter operating results.
Management will also provide a brief update on the business.
Conference Call InformationTo access the live call by
phone, dial 719-785-1753; the conference ID is 2275763. The call may
also be accessed through the Investors section of the Company’s website, www.immunogen.com.
Following the webcast, a replay of the call will be available at the
same location through August 10, 2018.
About ImmunoGenImmunoGen is developing the next generation
of antibody-drug conjugates (ADCs) to improve outcomes for cancer
patients. By generating targeted therapies with enhanced anti-tumor
activity and favorable tolerability profiles, we aim to disrupt the
progression of cancer and offer our patients more good days. We call
this our commitment to “target a better now.” Our lead product
candidate, mirvetuximab soravtansine, is in Phase 3 study for folate
receptor alpha (FR?)-positive platinum resistant ovarian cancer, and in
Phase 1b/2 testing in combination regimens. Our novel IGN candidates for
hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180712005760/en/